Search

Your search keyword '"Lurvink, Robin"' showing total 49 results
Start Over Author "Lurvink, Robin"
49 results on '"Lurvink, Robin"'

1. Patient-reported outcomes during first-line palliative systemic therapy alternated with pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-II)

Author

van de Vlasakker, Vincent C. J., Rauwerdink, Paulien, Rovers, Koen. P. B., Wassenaar, Emma C., Creemers, Geert-Jan, Los, Maartje, Burger, Jacobus . W. A., Nienhuijs, Simon W., Kranenburg, Onno, Wiezer, Marinus J., Lurvink, Robin J., Boerma, Djamila, and de Hingh, Ignace H. J. T.

Published
2024
Full Text
View/download PDF

2. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)

Author

Rauwerdink, Paulien, van de Vlasakker, Vincent C.J., Wassenaar, Emma C.E., Rovers, Koen P., Los, Maartje, Herbschleb, Karin H., Creemers, Geert-Jan M., Thijs, Annemarie M.J., Raicu, Mihaela G., Huysentruyt, Clément J.R., van der Hoeven, Erik J.R.J., Nederend, Joost, Peeters, Rifka Y.M., Deenen, Maarten J., Elias, Sjoerd G., Fijneman, Remond J.A., Constantinides, Alexander, Kranenburg, Onno, Burger, Pim W.A., Nienhuijs, Simon W., Wiezer, René J., Lurvink, Robin J., de Hingh, Ignace H.J.T., and Boerma, Djamila

Published
2024
Full Text
View/download PDF

3. Comparing patient reported abdominal pain between patients treated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) and primary colorectal cancer surgery

Author

van de Vlasakker, Vincent C. J., Lurvink, Robin J., Wassenaar, Emma C., Rauwerdink, Paulien, Bakkers, Checca, Rovers, Koen P., Bonhof, Cynthia S., Burger, Jacobus W. A., Wiezer, Marinus J., Boerma, Djamila, Nienhuijs, Simon W., Mols, Floortje, and de Hingh, Ignace H. J. T.

Published
2023
Full Text
View/download PDF

6. Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)

Author

Lurvink, Robin J., Rovers, Koen P., Wassenaar, Emma C. E., Bakkers, Checca, Burger, Jacobus W. A., Creemers, Geert-Jan M., Los, Maartje, Mols, Floortje, Wiezer, Marinus J., Nienhuijs, Simon W., Boerma, Djamila, and de Hingh, Ignace H. J. T.

Published
2022
Full Text
View/download PDF

7. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)

Author

van de Vlasakker, Vincent C.J., Lurvink, Robin J., Cashin, Peter H., Ceelen, Wim, Deraco, Marcello, Goéré, Diane, González-Moreno, Santiago, Lehmann, Kuno, Li, Yan, Moran, Brendan, Morris, David L., Piso, Pompiliu, Quadros, Claudio A., Rau, Beate, Somashekhar, S.P., Sommariva, Antonio, van der Speeten, Kurt, Spiliotis, John, Sugarbaker, Paul H., Teo, Melissa C.C., Verwaal, Vic J., Yonemura, Yutaka, Glehen, Olivier, and de Hingh, Ignace H.J.T.

Published
2021
Full Text
View/download PDF

8. Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC)

Author

Rovers, Koen P., Wassenaar, Emma C. E., Lurvink, Robin J., Creemers, Geert-Jan M., Burger, Jacobus W. A., Los, Maartje, Huysentruyt, Clément J. R., van Lijnschoten, Gesina, Nederend, Joost, Lahaye, Max J., Deenen, Maarten J., Wiezer, Marinus J., Nienhuijs, Simon W., Boerma, Djamila, and de Hingh, Ignace H. J. T.

Published
2021
Full Text
View/download PDF

10. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: Protocol of the multicentre, open-label, phase II, INTERACT-II trial

Author

Heelkundig Oncologische Disciplines, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., Burger, Jacobus W.A., Heelkundig Oncologische Disciplines, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., and Burger, Jacobus W.A.

Published
2024

11. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)

Author

Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Lab Translational Oncology, Heelkunde Opleiding, Regenerative Medicine and Stem Cells, Rauwerdink, Paulien, van de Vlasakker, Vincent C.J., Wassenaar, Emma C.E., Rovers, Koen P., Los, Maartje, Herbschleb, Karin H., Creemers, Geert Jan M., Thijs, Annemarie M.J., Raicu, Mihaela G., Huysentruyt, Clément J.R., van der Hoeven, Erik J.R.J., Nederend, Joost, Peeters, Rifka Y.M., Deenen, Maarten J., Elias, Sjoerd G., Fijneman, Remond J.A., Constantinides, Alexander, Kranenburg, Onno, Burger, Pim W.A., Nienhuijs, Simon W., Wiezer, René J., Lurvink, Robin J., de Hingh, Ignace H.J.T., Boerma, Djamila, Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Lab Translational Oncology, Heelkunde Opleiding, Regenerative Medicine and Stem Cells, Rauwerdink, Paulien, van de Vlasakker, Vincent C.J., Wassenaar, Emma C.E., Rovers, Koen P., Los, Maartje, Herbschleb, Karin H., Creemers, Geert Jan M., Thijs, Annemarie M.J., Raicu, Mihaela G., Huysentruyt, Clément J.R., van der Hoeven, Erik J.R.J., Nederend, Joost, Peeters, Rifka Y.M., Deenen, Maarten J., Elias, Sjoerd G., Fijneman, Remond J.A., Constantinides, Alexander, Kranenburg, Onno, Burger, Pim W.A., Nienhuijs, Simon W., Wiezer, René J., Lurvink, Robin J., de Hingh, Ignace H.J.T., and Boerma, Djamila

Published
2024

12. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases:Protocol of the multicentre, open-label, phase II, INTERACT-II trial

Author

Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., Burger, Jacobus W.A., Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., and Burger, Jacobus W.A.

Abstract

Introduction:The peritoneum is the second most affected organ for the dissemination of colorectal cancer (CRC). Patients with colorectal peritoneal metastases (CPM) face a poor prognosis, despite the majority of patients being treated with palliative systemic therapy. The efficacy of palliative systemic therapy is limited due to the plasma-peritoneum barrier. The poor prognosis of unresectable CPM patients has resulted in the development of new treatment strategies where systemic therapy is combined with local, intraperitoneal chemotherapy. In the recently published phase I study, the maximum tolerated dose and thus the recommended phase II dose of intraperitoneal irinotecan was investigated and determined to be 75 mg. In the present study, the overall survival after treatment with 75 mg irinotecan with concomitant mFOLFOX4 and bevacizumab will be investigated. Materials and methods:In this single-arm phase II study in two Dutch tertiary referral centres, 85 patients are enrolled. Eligibility criteria are an adequate performance status and organ function, histologically confirmed microsatellite stable and unresectable CPM, no previous palliative therapy for CRC, no systemic therapy<6 months for CRC prior to enrolment and no previous cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS and HIPEC). Patients will undergo a diagnostic laparoscopy as standard work-up for CPM and if the peritoneal disease is considered unresectable (eg, Peritoneal Cancer Index (PCI)>20, too extensive small bowel involvement), a peritoneal access port and a port-a-cath are placed for administration of intraperitoneal and intravenous chemotherapy, respectively. Patients may undergo up to 12 cycles of study treatment. Each cycle consists of intravenous mFOLFOX4 with bevacizumab and concomitant intraperitoneal irinotecan (75 mg), which is repeated every 2 weeks, with a maximum of 12 cycles. Modified FOLFOX-4 regimen consists of 8

Published
2024

14. Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial

Author

Lurvink, Robin J., Tajzai, Rudaba, Rovers, Koen P., Wassenaar, Emma C. E., Moes, Dirk-Jan A. R., Pluimakers, Giulia, Boerma, Djamila, Burger, Jacobus W. A., Nienhuijs, Simon W., de Hingh, Ignace H. J. T., and Deenen, Maarten J.

Published
2021
Full Text
View/download PDF

16. Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases

Author

van Eerden, Ruben A G, primary, de Boer, Nadine L, additional, van Kooten, Job P, additional, Bakkers, Checca, additional, Dietz, Michelle V, additional, Creemers, Geert-Jan M, additional, Buijs, Sanne M, additional, Bax, Ramon, additional, de Man, Femke M, additional, Lurvink, Robin J, additional, Diepeveen, Marjolein, additional, Brandt-Kerkhof, Alexandra R M, additional, van Meerten, Esther, additional, Koolen, Stijn L W, additional, de Hingh, Ignace H J T, additional, Verhoef, Cornelis, additional, Mathijssen, Ron H J, additional, and Burger, Jacobus W A, additional

Published
2023
Full Text
View/download PDF

17. Pressurized aerosol versus catheter-based intraperitoneal chemotherapy in patients with extensive colorectal peritoneal metastases – comparing results of two early phase trials.

Author

Van Den Heuvel, Teun, Van de Vlasakker, Vincent C.J., Rauwerdink, Paulien, van Eerden, Ruben A.G., de Boer, Nadine L., van Kooten, Job P., Lurvink, Robin J., Madsen, Eva V.E., Brandt-Kerkhof, Alexandra R.M., van Meerten, Esther, Nienhuijs, Simon W., Rovers, Koen P.B., Bakkers, Checca, Verhoef, Cornelis, Mathijssen, Ron H.J., Boerma, Djamila, de Hingh, Ignace H.J.T., and Burger, Jacobus W.A.

Published
2024
Full Text
View/download PDF

18. Palliative systemic therapy and oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with unresectable colorectal peritoneal metastases in a phase II trial (CRC-PIPAC-II)

Author

Van De Vlasakker, Vincent, primary, Rauwerdink, Paulien, additional, Rovers, Koen P., additional, Wassenaar, Emma C.E., additional, Deenen, Maarten J., additional, Nederend, Joost, additional, Huysentruyt, Clément J.R., additional, Fijneman, Remond J.A., additional, van der Hoeven, Erik J.R.J., additional, Raicu, Mihaela M., additional, Constantinides, Alexander, additional, Kranenburg, Onno, additional, Los, Maartje, additional, Creemers, Geert-Jan M., additional, Burger, Pim W.A., additional, Wiezer, René J., additional, Nienhuijs, Simon W., additional, Lurvink, Robin J., additional, Boerma, Djamila, additional, and de Hingh, Ignace H.J.T., additional

Published
2023
Full Text
View/download PDF

19. Intraperitoneal irinotecan combined with systemic chemotherapy for extensive peritoneal carcinomatosis of colorectal origin: The phase I and phase II INTERACT trials

Author

van Eerden, Ruben A.G., primary, Van De Vlasakker, Vincent, additional, Guchelaar, Niels A.D., additional, de Boer, Nadine L., additional, van kooten, Job P., additional, Bakkers, Checca, additional, Dietz, Michelle, additional, Creemers, Geert-Jan M., additional, Buijs, Sanne M., additional, Bax, Ramon, additional, de Man, Femke M., additional, Lurvink, Robin J., additional, Diepeveen, Marjolein, additional, Brandt-Kerkhof, Alexandra R.M., additional, van Meerten, Esther, additional, Koolen, Stijn L.W., additional, de Hingh, Ignace H.J.T., additional, Verhoef, Cornelis, additional, Mathijssen, Ron H.J., additional, and Burger, Pim W.A., additional

Published
2023
Full Text
View/download PDF

20. The Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) versus Conventional Surgery on Patient-Reported Outcomes: A Comparative Cohort Study between the CAIRO6 Trial and the PROCORE Study

Author

Bakkers, Checca, primary, van de Vlasakker, Vincent C. J., additional, Rovers, Koen P. B., additional, Lurvink, Robin J., additional, Nienhuijs, Simon W., additional, Burger, Jacobus W. A., additional, Creemers, Geert-Jan M., additional, Bonhof, Cynthia S., additional, Mols, Floortje, additional, and de Hingh, Ignace H. J. T., additional

Published
2023
Full Text
View/download PDF

21. Unresectable colorectal peritoneal metastases

Author

Lurvink, Robin, De Hingh, Ignace, Burger, J. W. A., van Erning, F.N., Epidemiologie, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
peritoneal metastases, PIPAC, palliative treatment, colorectal cancer
Abstract

This thesis provided an overview of the incidence, treatment, and prognosis of colorectal peritoneal metastases and focused on the potential role of treatment with PIPAC in the palliative setting. PIPAC is a new method of administering chemotherapy into the abdomen as a pressurized aerosol, with potential advantages over systemic chemotherapy. Despite the worldwide growing popularity of PIPAC, there is no scientific evidence that confirms the superiority or non-inferiority of PIPAC over systemic chemotherapy. Hence, two studies were initiated in the Netherlands to gain more insight into the side effects and tolerability, anti-tumour efficacy, and costs of treatment with PIPAC, and quality of life during treatment with PIPAC. The first study (CRC-PIPAC) focused on repetitive treatment with PIPAC every 4-6 weeks without systemic chemotherapy in between, the results of which are reported in this thesis. The second study (CRC-PIPAC-II) focused on repetitive PIPAC alternated with systemic chemotherapy, the results of which are expected over the course of 2022.

Published
2022
Full Text
View/download PDF

25. Patient-reported outcomes during repetitive pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase 2 trial

Author

Lurvink, Robin, primary, Rovers, Koen, additional, Wassenaar, Emma, additional, Bakkers, Checca, additional, Burger, Pim, additional, Creemers, Geert-Jan, additional, Los, Maartje, additional, Mols, Floortje, additional, Wiezer, René, additional, Nienhuijs, Simon, additional, Boerma, Djamila, additional, and de Hingh, Ignace, additional

Published
2022
Full Text
View/download PDF

26. The impact of open or laparoscopic surgery for colorectal cancer on the development of metachronous peritoneal metastases – results from a population-based cohort study

Author

Lurvink, Robin, primary, Rijken, Anouk, additional, Bakkers, Checca, additional, Lemmens, Valery, additional, de Reuver, Philip, additional, Tuynman, Jurriaan, additional, Kok, Niels, additional, Nienhuijs, Simon, additional, van Erning, Felice, additional, and de Hingh, Ignace, additional

Published
2022
Full Text
View/download PDF

27. Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)

Author

Lurvink, Robin J., primary, Rovers, Koen P., additional, Wassenaar, Emma C. E., additional, Bakkers, Checca, additional, Burger, Jacobus W. A., additional, Creemers, Geert-Jan M., additional, Los, Maartje, additional, Mols, Floortje, additional, Wiezer, Marinus J., additional, Nienhuijs, Simon W., additional, Boerma, Djamila, additional, and de Hingh, Ignace H. J. T., additional

Published
2021
Full Text
View/download PDF

29. RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers PIPAC-oxaliplatin for peritoneal metastases of gastrointestinal cancers

Author

Rovers, Koen P., Lurvink, Robin J., Deenen, Maarten J., de Hingh, Ignace H. J. T., Epidemiologie, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
CARCINOMATOSIS
Published
2021

30. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases : A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)

Author

van de Vlasakker, Vincent C. J., Lurvink, Robin J., Cashin, Peter H., Ceelen, Wim, Deraco, Marcello, Goéré, Diane, González-Moreno, Santiago, Lehmann, Kuno, Li, Yan, Moran, Brendan, Morris, David L., Piso, Pompiliu, Quadros, Claudio A., Rau, Beate, Somashekhar, S. P., Sommariva, Antonio, van der Speeten, Kurt, Spiliotis, John, Sugarbaker, Paul H., Teo, Melissa C. C., Verwaal, Vic J., Yonemura, Yutaka, Glehen, Olivier, de Hingh, Ignace H. J. T., van de Vlasakker, Vincent C. J., Lurvink, Robin J., Cashin, Peter H., Ceelen, Wim, Deraco, Marcello, Goéré, Diane, González-Moreno, Santiago, Lehmann, Kuno, Li, Yan, Moran, Brendan, Morris, David L., Piso, Pompiliu, Quadros, Claudio A., Rau, Beate, Somashekhar, S. P., Sommariva, Antonio, van der Speeten, Kurt, Spiliotis, John, Sugarbaker, Paul H., Teo, Melissa C. C., Verwaal, Vic J., Yonemura, Yutaka, Glehen, Olivier, and de Hingh, Ignace H. J. T.

Abstract

Introduction The PRODIGE 7-trial investigated the additional value of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to cytoreductive surgery (CRS) for patients with colorectal peritoneal metastases (CPM). The results of PRODIGE 7 were presented at the 2018 ASCO meeting showing that 30 min oxaliplatin-based HIPEC did not improve overall survival. The current study investigated the impact of PRODIGE 7 on the worldwide practice of CRS and HIPEC. Materials and methods CRS-HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning the current CRS-HIPEC practice in their hospital and country, and were asked to appraise the effect of PRODIGE 7. Results The survey was completed by 18/19 experts. Although their personal opinions of CRS-HIPEC were barely influenced by PRODIGE 7, they reported a substantial impact on daily practice. This included a switch towards Mitomycin-C based HIPEC-regimens and prolongation of HIPEC perfusion time, a reduction in the number of referrals from non-HIPEC centers, a reduction in national consensus, the removal of HIPEC from national guidelines, and a reduced reimbursement rate. Conclusion The PRODIGE 7 has had a major impact on the practice of CRS-HIPEC for CPM worldwide. HIPEC remains an attractive option with potential for control and eradication of disease and further studies into the optimal HIPEC-regimen are urgently needed. Meanwhile, given the complexity of the treatment of patients with CPM, and the proven benefits of optimal CRS, referral of patients with potentially resectable CPM to expert centers is recommended whilst the precise role of HIPEC is further evaluated.

Published
2021
Full Text
View/download PDF

31. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: Protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II)

Author

Research UMC Utrecht, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, Lurvink, Robin J., Rauwerdink, Paulien, Rovers, Koen P., Wassenaar, Emma C.E., Deenen, Maarten J., Nederend, Joost, Huysentruyt, Clément J.R., Van 'T Erve, Iris, Fijneman, Remond J.A., Van Der Hoeven, Erik J.R.J., Seldenrijk, Cornelis A., Constantinides, Alexander, Kranenburg, Onno, Los, Maartje, Herbschleb, Karin H., Thijs, Anna M.J., Creemers, Geert Jan M., Burger, Jacobus W.A., Wiezer, Marinus J., Nienhuijs, Simon W., Boerma, Djamila, De Hingh, Ignace H.J.T., Research UMC Utrecht, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, Lurvink, Robin J., Rauwerdink, Paulien, Rovers, Koen P., Wassenaar, Emma C.E., Deenen, Maarten J., Nederend, Joost, Huysentruyt, Clément J.R., Van 'T Erve, Iris, Fijneman, Remond J.A., Van Der Hoeven, Erik J.R.J., Seldenrijk, Cornelis A., Constantinides, Alexander, Kranenburg, Onno, Los, Maartje, Herbschleb, Karin H., Thijs, Anna M.J., Creemers, Geert Jan M., Burger, Jacobus W.A., Wiezer, Marinus J., Nienhuijs, Simon W., Boerma, Djamila, and De Hingh, Ignace H.J.T.

Published
2021

32. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid

Author

MS HOD, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, van't Erve, Iris, Rovers, Koen P., Constantinides, Alexander, Bolhuis, Karen, Wassenaar, Emma C.E., Lurvink, Robin J., Huysentruyt, Clément J., Snaebjornsson, Petur, Boerma, Djamila, van den Broek, Daan, Buffart, Tineke E., Lahaye, Max J., Aalbers, Arend G.J., Kok, Niels F.M., Meijer, Gerrit A., Punt, Cornelis J.A., Kranenburg, Onno, de Hingh, Ignace H.J.T., Fijneman, Remond J.A., MS HOD, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, van't Erve, Iris, Rovers, Koen P., Constantinides, Alexander, Bolhuis, Karen, Wassenaar, Emma C.E., Lurvink, Robin J., Huysentruyt, Clément J., Snaebjornsson, Petur, Boerma, Djamila, van den Broek, Daan, Buffart, Tineke E., Lahaye, Max J., Aalbers, Arend G.J., Kok, Niels F.M., Meijer, Gerrit A., Punt, Cornelis J.A., Kranenburg, Onno, de Hingh, Ignace H.J.T., and Fijneman, Remond J.A.

Published
2021

36. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II)

Author

Lurvink, Robin J., primary, Rauwerdink, Paulien, additional, Rovers, Koen P., additional, Wassenaar, Emma C.E., additional, Deenen, Maarten J., additional, Nederend, Joost, additional, Huysentruyt, Clément J.R., additional, van 't Erve, Iris, additional, Fijneman, Remond J.A., additional, van der Hoeven, Erik J.R.J., additional, Seldenrijk, Cornelis A., additional, Constantinides, Alexander, additional, Kranenburg, Onno, additional, Los, Maartje, additional, Herbschleb, Karin H., additional, Thijs, Anna M.J., additional, Creemers, Geert-Jan M., additional, Burger, Jacobus W.A., additional, Wiezer, Marinus J., additional, Nienhuijs, Simon W., additional, Boerma, Djamila, additional, and de Hingh, Ignace H.J.T., additional

Published
2021
Full Text
View/download PDF

37. Detection of tumor‐derived cell‐free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid

Author

van't Erve, Iris, primary, Rovers, Koen P, additional, Constantinides, Alexander, additional, Bolhuis, Karen, additional, Wassenaar, Emma CE, additional, Lurvink, Robin J, additional, Huysentruyt, Clément J, additional, Snaebjornsson, Petur, additional, Boerma, Djamila, additional, Broek, Daan, additional, Buffart, Tineke E, additional, Lahaye, Max J, additional, Aalbers, Arend GJ, additional, Kok, Niels FM, additional, Meijer, Gerrit A, additional, Punt, Cornelis JA, additional, Kranenburg, Onno, additional, Hingh, Ignace HJT, additional, and Fijneman, Remond JA, additional

Published
2021
Full Text
View/download PDF

38. 727 OUTCOMES OF FIRST-LINE PALLIATIVE SYSTEMIC THERAPY ALTERNATED WITH OXALIPLATIN-BASED PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY IN PATIENTS WITH UNRESECTABLE COLORECTAL PERITONEAL METASTASES IN A MULTICENTER, SINGLE-ARM, PHASE II TRIAL

Author

van de Vlasakker, Vincent C., Rauwerdink, Paulien, Rovers, Koen P., Wassenaar, Emma, Deenen, Maarten J., Nederend, Joost, Huysentruyt, Clement, Fijneman, Remond J., van der Hoeven, Erik, Raicu, G., Constantinidis, Alexander, Kranenburg, Onno, Los, Maartje, Creemers, Geert-Jan, burger, Jacobus, Wiezer, Marinus, Nienhuijs, Simon, Lurvink, Robin, Boerma, Djamila, and de Hingh, Ignace H.

Published
2023
Full Text
View/download PDF

39. Abstract 708: Limited release of circulating tumor DNA into the systemic circulation by peritoneal metastases from colorectal cancer

Author

van 't Erve, Iris, primary, Rovers, Koen P., additional, Constantinides, Alexander, additional, Bolhuis, Karen, additional, Wassenaar, Emma C., additional, Lurvink, Robin J., additional, Huysentruyt, Clément J., additional, Snaebjornsson, Petur, additional, van den Broek, Daan, additional, Buffart, Tineke E., additional, Kok, Niels F., additional, Meijer, Gerrit A., additional, Punt, Cornelis J., additional, Kranenburg, Onno, additional, de Hingh, Ignace H., additional, and Fijneman, Remond J., additional

Published
2020
Full Text
View/download PDF

40. Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial

Author

Lurvink, Robin J., primary, Tajzai, Rudaba, additional, Rovers, Koen P., additional, Wassenaar, Emma C. E., additional, Moes, Dirk-Jan A. R., additional, Pluimakers, Giulia, additional, Boerma, Djamila, additional, Burger, Jacobus W. A., additional, Nienhuijs, Simon W., additional, de Hingh, Ignace H. J. T., additional, and Deenen, Maarten J., additional

Published
2020
Full Text
View/download PDF

41. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC)

Author

Rovers, Koen P., Lurvink, Robin J., Wassenaar, Emma C. E., Kootstra, Thomas J. M., Scholten, Harm J., Tajzai, Rudaba, Deenen, Maarten J., Nederend, Joost, Lahaye, Max J., Huysentruyt, Clement J. R., van't Erve, Iris, Fijneman, Remond J. A., Constantinides, Alexander, Kranenburg, Onno, Los, Maartje, Thijs, Anna M. J., Creemers, Geert-Jan M., Burger, Jacobus W. A., Wiezer, Marinus J., Boerma, Djamila, Nienhuijs, Simon W., de Hingh, Ignace H. J. T., Rovers, Koen P., Lurvink, Robin J., Wassenaar, Emma C. E., Kootstra, Thomas J. M., Scholten, Harm J., Tajzai, Rudaba, Deenen, Maarten J., Nederend, Joost, Lahaye, Max J., Huysentruyt, Clement J. R., van't Erve, Iris, Fijneman, Remond J. A., Constantinides, Alexander, Kranenburg, Onno, Los, Maartje, Thijs, Anna M. J., Creemers, Geert-Jan M., Burger, Jacobus W. A., Wiezer, Marinus J., Boerma, Djamila, Nienhuijs, Simon W., and de Hingh, Ignace H. J. T.

Published
2019

42. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC)

Author

MS CGO, CMM Groep Coffer, Cancer, Regenerative Medicine and Stem Cells, Rovers, Koen P., Lurvink, Robin J., Wassenaar, Emma C. E., Kootstra, Thomas J. M., Scholten, Harm J., Tajzai, Rudaba, Deenen, Maarten J., Nederend, Joost, Lahaye, Max J., Huysentruyt, Clement J. R., van't Erve, Iris, Fijneman, Remond J. A., Constantinides, Alexander, Kranenburg, Onno, Los, Maartje, Thijs, Anna M. J., Creemers, Geert-Jan M., Burger, Jacobus W. A., Wiezer, Marinus J., Boerma, Djamila, Nienhuijs, Simon W., de Hingh, Ignace H. J. T., MS CGO, CMM Groep Coffer, Cancer, Regenerative Medicine and Stem Cells, Rovers, Koen P., Lurvink, Robin J., Wassenaar, Emma C. E., Kootstra, Thomas J. M., Scholten, Harm J., Tajzai, Rudaba, Deenen, Maarten J., Nederend, Joost, Lahaye, Max J., Huysentruyt, Clement J. R., van't Erve, Iris, Fijneman, Remond J. A., Constantinides, Alexander, Kranenburg, Onno, Los, Maartje, Thijs, Anna M. J., Creemers, Geert-Jan M., Burger, Jacobus W. A., Wiezer, Marinus J., Boerma, Djamila, Nienhuijs, Simon W., and de Hingh, Ignace H. J. T.

Published
2019

43. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC)

Author

Rovers, Koen P, primary, Lurvink, Robin J, additional, Wassenaar, Emma CE, additional, Kootstra, Thomas JM, additional, Scholten, Harm J, additional, Tajzai, Rudaba, additional, Deenen, Maarten J, additional, Nederend, Joost, additional, Lahaye, Max J, additional, Huysentruyt, Clément JR, additional, van ’t Erve, Iris, additional, Fijneman, Remond JA, additional, Constantinides, Alexander, additional, Kranenburg, Onno, additional, Los, Maartje, additional, Thijs, Anna MJ, additional, Creemers, Geert-Jan M, additional, Burger, Jacobus WA, additional, Wiezer, Marinus J, additional, Boerma, Djamila, additional, Nienhuijs, Simon W, additional, and de Hingh, Ignace HJT, additional

Published
2019
Full Text
View/download PDF

44. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, singlearm, phase II study (CRC-PIPAC)

Author

Rovers, Koen P., Lurvink, Robin J., Wassenaar, Emma C. E., Kootstra, Thomas J. M., Scholten, Harm J., Tajzai, Rudaba, Deenen, Maarten J., Nederend, Joost, Lahaye, Max J., Huysentruyt, Clément J. R., van 't Erve, Iris, Fijneman, Remond J. A., Constantinides, Alexander, Kranenburg, Onno, Los, Maartje, Thijs, Anna M. J., Creemers, Geert-Jan M., Burger, Jacobus W. A., Wiezer, Marinus J., and Boerma, Djamila

Abstract

Introduction Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little is known about its feasibility, safety, tolerability, efficacy, costs and pharmacokinetics in this setting. This study aims to explore these parameters in patients with isolated unresectable colorectal PM who receive repetitive ePIPAC-OX as a palliative monotherapy. Methods and analysis This multicentre, open-label, single-arm, phase II study is performed in two Dutch tertiary referral hospitals for the surgical treatment of colorectal PM. Eligible patients are adults who have histologically or cytologically proven isolated unresectable PM of a colorectal or appendiceal carcinoma, a good performance status, adequate organ functions and no symptoms of gastrointestinal obstruction. Instead of standard palliative treatment, enrolled patients receive laparoscopycontrolled ePIPAC-OX (92 mg/m2 body surface area (BSA)) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every 6 weeks. Four weeks after each procedure, patients undergo clinical, radiological and biochemical evaluation. ePIPAC-OX is repeated until disease progression, after which standard palliative treatment is (re)considered. The primary outcome is the number of patients with major toxicity (grade =3 according to the Common Terminology Criteria for Adverse Events v4.0) up to 4 weeks after the last ePIPAC-OX. Secondary outcomes are the environmental safety of ePIPAC-OX, procedure-related characteristics, minor toxicity, postoperative complications, hospital stay, readmissions, quality of life, costs, pharmacokinetics of oxaliplatin, progression-free survival, overall survival, and the radiological, histopathological, cytological, biochemical and macroscopic tumour response. Ethics and dissemination This study is approved by an ethics committee, the Dutch competent authority and the institutional review boards of both study centres. Results are intended for publication in peer-reviewed medical journals and for presentation to patients, healthcare professionals and other stakeholders. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

45. RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers: PIPAC-oxaliplatin for peritoneal metastases of gastrointestinal cancers

Author

Rovers, Koen P., Lurvink, Robin J., Deenen, Maarten J., and de Hingh, Ignace H.J.T.

Subjects
*AEROSOLS, *CANCER chemotherapy, *METASTASIS, *TUMOR classification, *GASTROINTESTINAL tumors, *LAPAROSCOPY, *OXALIPLATIN
Published
2021
Full Text
View/download PDF

47. Guidelines for the Prophylaxis and Treatment of Peritoneal Metastases From Colorectal Cancer: A GRADE-Approach for Evidence Evaluation and Recommendations.

Author

Goéré D, Kusamura S, Lurvink RJ, Cinquini M, Piso P, Levine E, Hubner M, Cortés Guiral D, Brandl A, Spinelli A, De Hingh IHJT, and Deraco M

Abstract

Colorectal peritoneal metastases (CPM) are common in colorectal cancer patients. This article aims to provide GRADE guidelines for the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in two clinical situations: (1) To determine the value of adjuvant HIPEC for the prevention of CPM in high-risk colorectal cancer patients; (2) to determine the impact on survival of cytoreductive surgery and HIPEC followed by adjuvant systemic chemotherapy as compared to systemic chemotherapy alone in patients with CPM., (© 2024 Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

48. Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival.

Author

van den Heuvel TBM, Lurvink RJ, Rovers KPB, van Hellemond IEG, and de Hingh IHJT

Abstract

In patients with resectable colorectal peritoneal metastases, it is unclear whether systemic chemotherapy, in addition to cytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), improves overall survival (OS). This systematic review of 12 retrospective studies involving 3721 patients aimed to summarize the available evidence. Contradictory results were found regarding the effectiveness of neoadjuvant, adjuvant, and perioperative systemic therapies on OS, with a high risk of bias. Available evidence remains inconclusive, stressing the need for prospective, randomized trials, like the ongoing Dutch CAIRO6-trial., (© 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

49. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.

Author

van de Vlasakker VCJ, Guchelaar NAD, van den Heuvel TBM, Lurvink RJ, van Meerten E, Bax RJF, Creemers GM, van Hellemond IEG, Brandt-Kerkhof ARM, Madsen EVE, Nederend J, Koolen SLW, Nienhuijs SW, Kranenburg O, de Hingh IHJT, Verhoef C, Mathijssen RHJ, and Burger JWA

Subjects
Humans, Bevacizumab therapeutic use, Irinotecan therapeutic use, Peritoneum, Fluorouracil, Leucovorin, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials, Phase II as Topic, Multicenter Studies as Topic, Peritoneal Neoplasms secondary, Colorectal Neoplasms surgery
Abstract

Introduction: The peritoneum is the second most affected organ for the dissemination of colorectal cancer (CRC). Patients with colorectal peritoneal metastases (CPM) face a poor prognosis, despite the majority of patients being treated with palliative systemic therapy. The efficacy of palliative systemic therapy is limited due to the plasma-peritoneum barrier. The poor prognosis of unresectable CPM patients has resulted in the development of new treatment strategies where systemic therapy is combined with local, intraperitoneal chemotherapy. In the recently published phase I study, the maximum tolerated dose and thus the recommended phase II dose of intraperitoneal irinotecan was investigated and determined to be 75 mg. In the present study, the overall survival after treatment with 75 mg irinotecan with concomitant mFOLFOX4 and bevacizumab will be investigated., Materials and Methods: In this single-arm phase II study in two Dutch tertiary referral centres, 85 patients are enrolled. Eligibility criteria are an adequate performance status and organ function, histologically confirmed microsatellite stable and unresectable CPM, no previous palliative therapy for CRC, no systemic therapy<6 months for CRC prior to enrolment and no previous cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS and HIPEC). Patients will undergo a diagnostic laparoscopy as standard work-up for CPM and if the peritoneal disease is considered unresectable (eg, Peritoneal Cancer Index (PCI)>20, too extensive small bowel involvement), a peritoneal access port and a port-a-cath are placed for administration of intraperitoneal and intravenous chemotherapy, respectively. Patients may undergo up to 12 cycles of study treatment. Each cycle consists of intravenous mFOLFOX4 with bevacizumab and concomitant intraperitoneal irinotecan (75 mg), which is repeated every 2 weeks, with a maximum of 12 cycles. Modified FOLFOX-4 regimen consists of 85 mg/m 2 oxaliplatin plus 200 mg/m 2 LV and 5-FU 400 mg/m 2 bolus on day 1 followed by 1600 mg/m 2 5-FU as a 46 hours infusion. Study treatment ends after the 12th cycle, or earlier in case of disease progression or unacceptable toxicity. The primary outcome is overall survival and key secondary outcomes are progression-free survival, safety (measured by the amount of grade ≥3 adverse events (Common Terminology Criteria for Adverse Events V.5.0)), patient-reported outcomes and pharmacokinetics of irinotecan. It is hypothesised that the trial treatment will lead to a 4 month increase in overall survival; from a median of 12.2 to 16.2 months., Ethics and Dissemination: This study is approved by the Dutch Authority (CCMO, the Hague, the Netherlands), by a central medical ethics committee (MEC-U, Nieuwegein, the Netherlands) and by the institutional research boards of both research centres. Results will be submitted for publication in peer-reviewed medical journals and presented to patients and healthcare professionals., Trial Registration Number: NCT06003998., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results